SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
2395・Prime Market・Services
Governance
Company with a Board of Corporate Auditors system. The Board of Directors comprises 12 members (including 6 outside directors, a 50% outside ratio), and the company has established a voluntary advisory Corporate Governance and Nomination Committee as well as a Compensation Committee. The Board of Directors met 13 times in FY2026 (ending March 2026), with all outside directors maintaining a high attendance rate.
Risk Management
The company has established a Reliability Assurance Department specializing in compliance with legal regulations such as GLP and GCP, identifying and managing risks and opportunities for each of the seven materiality items. The Board of Directors provides oversight, the Management Committee formulates risk management policies, and a system has been built to share information company-wide through the Executive Officers' Meeting.
Shareholder Returns
Stable dividends are the basic policy. The annual dividend for FY2026 (ending March 2026) is ¥50 per share (interim ¥20 + year-end ¥30), with a payout ratio of 45.6%. The same ¥50 dividend is planned for FY2027 (ending March 2027) (forecast payout ratio of 59.5%). A small-scale share buyback has been conducted.
Dividend Policy
The company regards stable dividend payments to shareholders as one of its important management policies, and its basic policy is to pay dividends twice a year, as an interim dividend and a year-end dividend. As a financial KPI target for FY2028, the company sets a payout ratio of 30-40%. The annual dividend for FY2026 (ending March 2026) is ¥50 per share (interim ¥20 + year-end ¥30), with total dividends of ¥2,081 million and a payout ratio of 45.6%. For FY2027 (ending March 2027), the company expects to continue paying an annual dividend of ¥50 per share (interim ¥20 + year-end ¥30), with a forecast payout ratio of 59.5%.
ESG
Guided by its corporate philosophy of "a company that values the environment, life, and people," the company promotes sustainability management through its SDGs Committee (chaired by an outside director, meeting monthly) and Environment Committee. In May 2026, it submitted to SBTi a target aligned with the 1.5°C pathway to reduce Scope 1 & 2 emissions by 58.8% (by FY2035, ending March 2035), and it has obtained and maintains AAALAC International accreditation for animal welfare.
Last updated: June 25, 2026